European Medicines Agency Grants Orphan Drug Designation to RBD1016 for Treatment of Hepatitis D Virus (HDV) Infection

Strategic Insights -

The European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of HDV infection, a rare and severe form of viral hepatitis. This designation is a significant regulatory milestone that enhances the development and commercial potential of RBD1016, a siRNA drug candidate designed to selectively silence key viral factors involved in HDV infection. RBD1016 is currently being assessed in global Phase II clinical development, offering a promising path forward for patients and clinicians seeking more effective and durable treatment options.

Key Takeaways:

  • The EMA's ODD is assigned to investigational therapies for life-threatening or chronically debilitating rare diseases that affect no more than five in 10,000 individuals in the European Union.
  • RBD1016 is a siRNA drug candidate designed to selectively silence key viral factors involved in HDV infection, leveraging Ribocure Pharmaceuticals AB's proprietary GalNAc-platform RiboGalSTAR TM.
  • The EMA's ODD status provides significant regulatory and commercial incentives, enabling more rapid progression to patients.
  • HDV is the most severe form of viral hepatitis, occurring only in individuals co-infected with hepatitis B virus (HBV), and is estimated to affect 12-20 million people globally.
  • Ribo, a pioneer in advancing RNAi technology, has established an oligonucleotide therapeutic platform that vertically integrates the complete set of technologies and has built a globally integrated drug development capability.

Statistics:

  • 12-20 million people globally are estimated to be affected by HDV.
  • RBD1016 is currently being assessed in global Phase II clinical development.
  • The EMA's ODD status provides significant regulatory and commercial incentives, enabling more rapid progression to patients.
  • Ribo has built a globally integrated drug development capability and a rich siRNA pipeline.

Sources:

  • Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo)
  • European Medicines Agency (EMA)
  • World Health Organization (WHO)
  • International Journal of Hepatology